<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181388</url>
  </required_header>
  <id_info>
    <org_study_id>64456541</org_study_id>
    <nct_id>NCT01181388</nct_id>
  </id_info>
  <brief_title>Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients</brief_title>
  <acronym>SUIT-AMI</acronym>
  <official_title>Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <brief_summary>
    <textblock>
      Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce
      bleeding complications in AMI patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>1 month after PCI</time_frame>
    <description>Infarct size, reinfarction, motality, et.al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>3 months after PCI</time_frame>
    <description>Infarct size, reinfarction, motality, et.al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>6 months after PCI</time_frame>
    <description>Infarct size, reinfarction, motality, et.al.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with bleeding events</measure>
    <time_frame>1 month</time_frame>
    <description>bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>intra-guide-catheter infusion of tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-thrombus-aspiration-catheter infusion of tirofiban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>administration of tirofiban by thrombus aspiration catheter in infarct-related artery</intervention_name>
    <description>a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI</description>
    <arm_group_label>intra-thrombus-aspiration-catheter infusion of tirofiban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>administration of tirofiban by guide catheter</intervention_name>
    <description>a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI</description>
    <arm_group_label>intra-guide-catheter infusion of tirofiban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patients

          -  chest pain for less than 12hr

          -  plan to PCI

        Exclusion Criteria:

          -  LM lesion

          -  stent thrombosis

          -  cardiac shock

          -  thrombocytopenia

          -  allergy to asprin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaoping Wang, MD, PhD</last_name>
    <phone>+861064456995</phone>
    <email>wang_shaoping@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunpeng Chi, MD</last_name>
    <phone>+861064456541</phone>
    <email>chiyunpeng0711@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the 28th division, Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoping Shaoping, MD. PhD</last_name>
      <phone>+861064456995</phone>
      <email>wang_shaoping@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yunpeng Chi, MD</last_name>
      <phone>+861064456541</phone>
      <email>chiyunpeng0711@sohu.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>August 12, 2010</last_update_submitted>
  <last_update_submitted_qc>August 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hongbing Yan</name_title>
    <organization>the 28th Division, Beijing Anzhen Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

